Variance in treatment compliance and costs by antidepressant class: Analysis in an HMO setting

Formulary

Volumn 36, Issue 3, 2001, Pages 204-210

  Baker, A M ^a   Russell, J M ^a   Campbell, J K ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; MAPROTILINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ARTICLE; COHORT ANALYSIS; DEPRESSION; DRUG CLASSIFICATION; DRUG COST; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY;

EID: 0035103570     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Antidepressant side effects and physician prescribing patterns
2. Trends in the prescription of antidepressants by office-based psychiatrists
3. Comparative tolerability profiles of the newer versus older antidepressants
4. Cost-effectiveness of newer antidepressants
5. Are SSRIs a cost-effective alternative to tricyclics?
6. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization
7. Economic evaluation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression
8. Initial antidepressant choice in primary care
9. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care
10. Effect of antidepressant therapy on health care utilization and costs in primary care
11. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: A multivariate analysis
12. Cost implications of initial antidepressant selection in primary care
13. Fluoxetine. A pharmacoeconomic review of its use in depression
14. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis
15. Direct cost of depression: Analysis of treatment costs of paroxetine versus imipramine in Canada
16. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis
17. Selective serotonin reuptake inhibitors. Assessment for formulary inclusion
18. Reducing the economic burden of depression
19. Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions
20. Antidepressant use and resource utilization in the general practitioner setting in the Netherlands
21. The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients
22. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment
23. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment
24. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses
25. The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics
26. A critical review of selected pharmacoeconomic analyses of antidepressant therapy
27. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings
28. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline
29. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder
30. The role of rating scales in the identification and management of the depressed patient in the primary care setting
31. Effect of primary care treatment of depression on service use by patients with high medical expenditures
32. Antidepressant selection and use and healthcare expenditures. An empirical approach